Korsana Biosciences Raises $175M to Advance Next-Generation Alzheimer’s Antibody

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative diseases, initially focusing on Alzheimer’s disease. The financing includes a $25 million seed round in 2024 led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A in September 2025 co-led by Wellington Management and TCGX, with participation from J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, and Foresite Capital. The company expects its current capital to support operations through key clinical milestones in 2027, with runway extending into 2028.

Read full article here.